Inactief instrument

Andere talen Viracta Therapeutics, Inc. Nasdaq

Aandelen

US92765F1084

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	07/05
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma	16/04
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	15/04
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	15/04
Viracta Therapeutics : HST 2024 – Presentation	15/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01/04
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	21/03
Viracta Therapeutics, Inc. Announces Executive Changes	20/03
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	20/03
North American Morning Briefing : Inflation -2-	15/03
Sunesis: Q4 Earnings Snapshot	07/03
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial	29/02
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Viracta Therapeutics, Inc. Provides Clinical Update	04/01
Viracta Therapeutics Provides Clinical Update and Outlook for 2024	04/01
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Viracta Therapeutics, Inc. Nasdaq

Aandelen

US92765F1084

Andere talen

Filters